Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Thomas Loughran Jr MD

Thomas P. Loughran Jr MD

F. Palmer Weber-Smithfield Foods Professor in Oncology Research, University of Virginia School of Medicine; Director, University of Virginia Cancer Center, Charlottesville, Virginia

Thomas P. Loughran, Jr., MD, is the Director of the University of Virginia Cancer Center, F. Palmer Weber-Smithfield Foods Professor of Oncology Research and Professor of Medicine. From July 2003 to August 2013, he served as the founding director of the Penn State Hershey Cancer Institute and Professor of Medicine at the Penn State College of Medicine. He previously served as program leader of hematologic malignancies at the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, associate director of the Bone Marrow Transplant Program at SUNY Health Science Center, and chief of hematology at the Syracuse Veteran's Affairs Medical Center in Syracuse, N.Y. He completed his fellowship in medical oncology at the Fred Hutchinson Cancer Research Center under direction of Nobel Laureate, Dr. E.D. Thomas and remained on faculty there for seven years.

His career as a physician scientist is a testament to translational research beginning with his discovery of large granular lymphocyte (LGL) leukemia. He has published numerous articles in high impact peer-reviewed journals including The New England Journal of Medicine, Annals of Internal Medicine, Lancet, Journal of Clinical Investigation, Journal of Clinical Oncology, and Blood.

Disclosures

Dr. Loughran is on the scientific advisory board and has stock options for Keystone Nano, Bioniz Therapeutics, Dren Bio and Recludix Pharma. He has also received an honorarium from Kymera Therapeutics.